{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:10:50Z","timestamp":1764238250569},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,12]]},"DOI":"10.7759\/cureus.66704","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T16:08:16Z","timestamp":1723478896000},"source":"Crossref","is-referenced-by-count":1,"title":["A Novel Treatment for Skin Manifestations in Dermatomyositis: A Case Report"],"prefix":"10.7759","author":[{"given":"Manasa","family":"Srinivasa Murthy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Haikal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-016-0816-8","article-title":"A mild form of dermatomyositis as a prodromal sign of lung adenocarcinoma: a case report","volume":"10","author":"Papakonstantinou E","year":"2016","unstructured":"Papakonstantinou E, Kapp A, Raap U. A mild form of dermatomyositis as a prodromal sign of lung adenocarcinoma: a case report. J Med Case Rep. 2016, 10:34. 10.1186\/s13256-016-0816-8","journal-title":"J Med Case Rep"},{"key":"ref2","article-title":"Dermatomyositis","author":"Qudsiya Z","year":"2024","unstructured":"Qudsiya Z, Waseem M. Dermatomyositis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5252","article-title":"Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis","volume":"9","author":"Castillo RL","year":"2021","unstructured":"Castillo RL, Femia AN. Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis. Ann Transl Med. 2021, 9:436. 10.21037\/atm-20-5252","journal-title":"Ann Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200607060-00002","article-title":"Management of cutaneous dermatomyositis: current therapeutic options","volume":"7","author":"Quain RD","year":"2006","unstructured":"Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006, 7:341-51. 10.2165\/00128071-200607060-00002","journal-title":"Am J Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2017.05.001","article-title":"The systemic management of cutaneous dermatomyositis: results of a stepwise strategy","volume":"3","author":"Anyanwu CO","year":"2017","unstructured":"Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP. The systemic management of cutaneous dermatomyositis: results of a stepwise strategy. Int J Womens Dermatol. 2017, 3:189-94. 10.1016\/j.ijwd.2017.05.001","journal-title":"Int J Womens Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang PS","year":"2024","unstructured":"Ang PS, Ezenwa E, Ko K, Hoffman MD. Refractory dermatomyositis responsive to anifrolumab. JAAD Case Rep. 2024, 43:27-9. 10.1016\/j.jdcr.2023.10.023","journal-title":"JAAD Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand EF","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al.. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020, 382:211-21. 10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons","volume":"12","author":"Greenberg SA","year":"2010","unstructured":"Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2010, 12:198-203. 10.1007\/s11926-010-0101-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: a review","volume":"31","author":"Bolko L","year":"2021","unstructured":"Bolko L, Jiang W, Tawara N, Landon-Cardinal O, Anquetil C, Benveniste O, Allenbach Y. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 2021, 31:e12955. 10.1111\/bpa.12955","journal-title":"Brain Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.41598","article-title":"Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study","volume":"73","author":"Chatham WW","year":"2021","unstructured":"Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, Tummala R. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study. Arthritis Rheumatol. 2021, 73:816-25. 10.1002\/art.41598","journal-title":"Arthritis Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/272255-a-novel-treatment-for-skin-manifestations-in-dermatomyositis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T16:08:18Z","timestamp":1723478898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/272255-a-novel-treatment-for-skin-manifestations-in-dermatomyositis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.66704","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,12]]}}}